Rapid, On-Site Manufacturing of CAR T-Cells (RFT-538)

Generate a PDF of this technology.

Generate PDF

Invention Summary


Scientists at NDSU have developed a device for improved CAR T cell production, which speeds the turnaround time by enabling CAR T cell production ‘on-site’ at a hospital or cancer clinic. The NDSU device is small and disposable. The device expands a patient’s T cells, and is then used to transfect them. Further, the cells are transfected with CAR-producing mRNA, for transient production of CAR for about 2 to 3 weeks.  Because this process takes place at the clinic, a physician can a have another treatment ready when the preceding treatments winds down, and the physician can also adjust each treatment (number of CAR T cells and CAR molecules per cell) to optimize treatment of the existing cancer while minimizing adverse effects.  The NDSU device doesn’t use viruses and there is no genome modification of T cells.


  • More rapid turnaround of therapeutic CAR T Cells than sending to specialized facility
  • Allow physicians to personalize therapy to address an individual’s needs (e.g. number of cells, expression levels of CAR molecules, and frequency of the dose)
  • Allow physicians to rapidly adjust treatment parameters, e.g. in cases where patients have over- or under-reaction to the initial approach, thereby reducing the degree and duration of side-effects
  • Enables miniaturization and automation, and eliminates dependence on costly external laboratory services, substantially reducing the costs to provide CAR T therapy
  • Vital vector free CAR T-cells for safe and personalized cancer therapy


This technology is patent pending in the U.S. and is available for licensing/partnering opportunities.


Henry Nowak, Technology Manager


RFT, 538, RFT538

Inquire about this technology >